nChroma Bio
92 employees
Biotech/Pharma
Series A · $75.0M
Open positions (3)
Company details
Team Size92
IndustryBiotech/Pharma
Funding
Total raised
$75.0M
Last stage
Series A
Investors
Atlas Venture
Total raised
$75.0M
Last stage
Series A
Investors
Jeff Walsh
Over 30 years of leadership in life sciences. Former CEO of Nvelop Therapeutics, previously Venture Partner at Third Rock Ventures, and held key executive roles at bluebird bio including CFO/CSO and COO.
LinkedInDavid Liu
Richard Merkin Professor and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT; Professor of Chemistry and Chemical Biology at Harvard University; pioneer in base editing and epigenetic editing.
Keith Joung
Desmond and Ann Heathwood Research Scholar and Pathologist at Massachusetts General Hospital; Professor of Pathology at Harvard Medical School; pioneer in genome and epigenome editing.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.